Literature DB >> 7773149

Comparative analysis of cytokines released by bone marrow stromal cells from normal donors and B-cell chronic lymphocytic leukemic patients.

L Lagneaux1, A Delforge, D Bron, E Bosmans, P Stryckmans.   

Abstract

We studied the production of cytokines (G-CSF, GM-CSF, IL-6, LIF and IL-10) by bone marrow stromal cells of five untreated patients with B-CLL, in Rai stage 0, I and II, and of 8 healthy subjects. The production of G-CSF, GM-CSF, LIF and IL-10 did not differ significantly between controls and B-CLL patients. However, the ability of stromal cells to release IL-6 in response to LPS was decreased in all patients: 36 +/- 5 ng/ml versus 123 +/- 47 ng/ml for normal controls (p < 0.004). Moreover, a soluble activity that inhibited hematopoietic colony formation was detected in B-CLL stromal cell conditioned media. Some potential inhibitors were envisaged and the results indicated an increased production of TGF-beta by B-CLL stromal cells compared to normal stromal cells (respectively 53 +/- 10 versus 15 +/- 4 ng/ml, p < 0.03). The reduced capacity of B-CLL stromal cells to produce IL-6 was associated with this excessive release of TGF-beta; indeed, addition of anti-TGF-beta neutralizing antibody to B-CLL stromal cells, before LPS stimulation, totally normalized the production of IL-6. TGF-beta and IL-6 were also measured in serum samples from normal subjects and B-CLL patients. No significant difference was seen in the production of total TGF-beta (bioactive and latent forms) between normal and B-CLL sera but the mean level of bioactive protein in B-CLL sera was increased in comparison with normal sera (1.74 +/- 0.44 versus 0.67 +/- 0.2 ng/ml, p < 0.04).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7773149     DOI: 10.3109/10428199509051712

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  4 in total

1.  Study of the quantitative, functional, cytogenetic, and immunoregulatory properties of bone marrow mesenchymal stem cells in patients with B-cell chronic lymphocytic leukemia.

Authors:  Charalampos Pontikoglou; Maria-Christina Kastrinaki; Mirjam Klaus; Christina Kalpadakis; Pavlos Katonis; Kalliopi Alpantaki; Gerassimos A Pangalis; Helen A Papadaki
Journal:  Stem Cells Dev       Date:  2013-02-01       Impact factor: 3.272

Review 2.  Role of transforming growth factor-beta in hematologic malignancies.

Authors:  Mei Dong; Gerard C Blobe
Journal:  Blood       Date:  2006-02-16       Impact factor: 22.113

3.  Bone marrow osteoblast damage by chemotherapeutic agents.

Authors:  Stephanie L Rellick; Heather O'Leary; Debbie Piktel; Cheryl Walton; James E Fortney; Stephen M Akers; Karen H Martin; James Denvir; Goran Boskovic; Donald A Primerano; Jeffrey Vos; Nathanael Bailey; Marieta Gencheva; Laura F Gibson
Journal:  PLoS One       Date:  2012-02-17       Impact factor: 3.240

Review 4.  Transforming Growth Factor-Beta Orchestrates Tumour and Bystander Cells in B-Cell Non-Hodgkin Lymphoma.

Authors:  Matthew A Timmins; Ingo Ringshausen
Journal:  Cancers (Basel)       Date:  2022-03-31       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.